Edition:
United States

Galena Biopharma Inc (GALE.OQ)

GALE.OQ on NASDAQ Stock Exchange Capital Market

0.31USD
15 Dec 2017
Change (% chg)

$-0.00 (-1.56%)
Prev Close
$0.32
Open
$0.33
Day's High
$0.33
Day's Low
$0.28
Volume
196,424
Avg. Vol
94,985
52-wk High
$3.60
52-wk Low
$0.26

Chart for

About

Galena Biopharma, Inc. is a biopharmaceutical company. The Company focuses on developing and commercializing targeted oncology therapeutics that address unmet medical needs. The Company's development portfolio ranges from mid- to late-stage clinical assets, including cancer immunotherapy program led by NeuVax (nelipepimut-S),... (more)

Overall

Beta: 1.96
Market Cap(Mil.): $14.40
Shares Outstanding(Mil.): 45.71
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 32.20 16.04
EPS (TTM): -- -- --
ROI: -- 15.06 35.70
ROE: -- 16.55 15.40

BRIEF-Galena Will Adjourn Special Meeting Until Friday, Dec 29

* GALENA WILL ADJOURN SPECIAL MEETING UNTIL FRIDAY, DECEMBER 29, 2017, URGES STOCKHOLDERS TO VOTE

Dec 14 2017

BRIEF-Galena Biopharma posts Q3 loss $0.15/shr from continuing operations

* Galena Biopharma reports third quarter 2017 financial results

Nov 09 2017

BRIEF-Galena Biopharma says co and Cardinal Health entered into a settlement relating to product swap agreement​

* Galena Biopharma Inc says on October 12, co and Cardinal Health entered into a settlement relating to product swap agreement​ - SEC filing

Oct 18 2017

BRIEF-Galena Biopharma announces completion of enrollment in two NeuVax™ clinical trials in combination with Trastuzumab

* Galena Biopharma Inc announces completion of enrollment in two NeuVax™ (nelipepimut-s) clinical trials in combination with Trastuzumab

Sep 28 2017

BRIEF-Kadmon announces proposed public offering of common stock and warrants

* Galena Biopharma-Nasdaq notified co eligible for additional 180-day grace period,until March 19, 2018,to regain compliance with minimum bid price requirement​ Source text: (http://reut.rs/2y52F5a) Further company coverage:

Sep 25 2017

BRIEF-Galena Biopharma, unit of co and Biovascular, enters amendment of exclusive license agreement

* Galena Biopharma-‍on Sept 5, unit of co and Biovascular, entered amendment of exclusive license agreement between MPI and BVI dated December 20, 2013

Sep 11 2017

BRIEF-Galena Biopharma and Biovascular Inc reaffirm GALE-401 partnership

* Galena Biopharma and Biovascular Inc reaffirm GALE-401 partnership

Sep 11 2017

Galena settles U.S. kickback charges related to opioid drug

Galena Biopharma Inc will pay more than $7.55 million to resolve charges it paid kickbacks to doctors to induce them to prescribe its opioid-based pain medication Abstral to patients, the U.S. Department of Justice said on Friday.

Sep 08 2017

UPDATE 1-Galena settles U.S. kickback charges related to opioid drug

Sept 8 Galena Biopharma Inc will pay more than $7.55 million to resolve charges it paid kickbacks to doctors to induce them to prescribe its opioid-based pain medication Abstral to patients, the U.S. Department of Justice said on Friday.

Sep 08 2017

BRIEF-U.S. DOJ says Galena Biopharma to pay over $7.55 mln to resolve alleged claims

* Department of Justice says "Galena Biopharma Inc to pay more than $7.55 million to resolve alleged false claims related to opioid drug"

Sep 08 2017

Competitors

Earnings vs. Estimates